Novel Compounds 569

Abstract

The present invention provides compounds of formula (I) wherein R a , R b , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 29 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

1 - 14 . (canceled) 
     
     
         15 . A method of treating, or reducing the risk of, a disease or condition in which modulation of β2 adrenoreceptor activity is beneficial which comprises administering to a patient in need thereof a therapeutically effective amount of N-Cyclohexyl-N 3 -[2-(3-fluorophenyl)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-β-alaninamide or a pharmaceutically acceptable salt thereof. 
     
     
         16 . A method of treating, or reducing the risk of, an inflammatory disease or condition which comprises administering to a patient in need thereof a therapeutically effective amount of N-Cyclohexyl-N 3 -[2-(3-fluorophenyl)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-β-alaninamide or a pharmaceutically acceptable salt thereof. 
     
     
         17 . A method according to  claim 15  or  claim 16 , wherein the disease or condition is adult respiratory distress syndrome (ARDS). 
     
     
         18 . (canceled) 
     
     
         19 . A method according to  claim 15  or  claim 16 , wherein the disease or condition is pulmonary emphysema. 
     
     
         20 . A method according to  claim 15  or  claim 16 , wherein the disease or condition is bronchitis. 
     
     
         21 . A method according to  claim 15  or  claim 16 , wherein the disease or condition is bronchiectasis. 
     
     
         22 . A method according to  claim 15  or  claim 16 , wherein the disease or condition is chronic obstructive pulmonary disease (COPD). 
     
     
         23 . A method according to  claim 15  or  claim 16 , wherein the disease or condition is asthma. 
     
     
         24 . A method according to  claim 15  or  claim 16 , wherein the disease or condition is rhinitis. 
     
     
         25 . A method according to  claim 15  or  claim 16 , wherein the method comprises administering to the patient in need thereof a therapeutically effective amount of N-Cyclohexyl-N 3 -[2-(3-fluorophenyl)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-β-alaninamide. 
     
     
         26 . A method according to  claim 15  or  claim 16 , wherein the method comprises administering to the patient in need thereof a therapeutically effective amount of N-Cyclohexyl-N 3 -[2-(3-fluorophenyl)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl) ethyl]amino}ethyl)-β-alaninamide in the form of a pharmaceutically acceptable salt, wherein the salt is an acid addition salt which is selected from the group consisting of hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulphonate, and p-toluenesulphonate.